Murcia's public health research foundation specializing in translational oncology, sepsis diagnostics, and clinical validation for EU collaborative projects.
FFIS is the health research foundation of the Murcia region in Spain, serving as the R&D arm of the regional public health system. They conduct clinical and translational research in oncology, immunology, and infectious disease — particularly sepsis diagnostics, cancer immunotherapy, and environmental health impacts. Their work bridges hospital-based clinical expertise with EU-funded collaborative research, contributing patient data, biomarker validation, and clinical trial infrastructure to large multinational projects.
ULISES (pancreatic cancer immunotherapy via allogenic response), REVERT (colorectal cancer combinatorial therapy), and SPEDI-TEST (sepsis biomarker, coordinator role) demonstrate deep oncology and immunology expertise.
SPEDI-TEST developed a prognostic test for septic patients based on NLRP3 detection, while ULISES explored immunological incompatibility markers for cancer.
PLASTICHEAL (their largest funded project at EUR 502,500) investigates micro/nanoplastics effects on human health using multi-omics and biomonitoring approaches.
ProEmpower focused on ICT for type 2 diabetes self-management, while PHArA-ON explored smart wearables and AI for healthy ageing.
REVERT includes an AI-based decision support system for cancer treatment, and PHArA-ON applied artificial intelligence to elderly care platforms.
FFIS began its H2020 participation (2016-2019) focused on digital health and ICT — diabetes management tools, demand-driven innovation procurement, and smart wearables for elderly care, with keywords like cloud computing, big data, and AI platforms. From 2020 onward, they pivoted sharply toward molecular medicine and translational oncology: cancer immunotherapy, nanoplastics health impact, sepsis biomarkers, and computational models for cancer progression. This shift suggests the foundation moved from being a clinical end-user of digital tools to an active contributor in wet-lab and translational biomedical research.
FFIS is deepening its molecular and translational medicine capabilities, particularly in cancer immunotherapy and environmental health biomonitoring — expect future proposals in precision oncology and exposure science.
FFIS operates predominantly as a supporting contributor rather than a consortium leader — they coordinated only 1 of 7 projects (SPEDI-TEST, an ERC Proof of Concept), and participated as a third party in 3 others, suggesting they often join through existing institutional partnerships rather than direct consortium membership. With 119 unique partners across 19 countries, they connect broadly but don't anchor large consortia. Their pattern of third-party involvement indicates they contribute specific clinical expertise or patient cohorts to projects led by others.
FFIS has collaborated with 119 distinct partners across 19 countries, indicating wide European reach despite their regional foundation status. Their network spans clinical research institutions, technology developers, and university hospitals typical of health-focused H2020 consortia.
FFIS offers something uncommon: a regional health system's research foundation with direct access to clinical infrastructure, patient cohorts, and hospital-embedded researchers — making them an ideal partner for projects needing real-world clinical validation in Spain. Their dual capability in both digital health platforms and molecular oncology means they can contribute to projects spanning from AI-assisted diagnostics to wet-lab biomarker discovery. For consortium builders targeting Southern European clinical sites, FFIS brings institutional stability and public health system integration that independent research groups cannot match.
